ArticleBMC medical informatics and decision making2025
Machine learning in early screening for high-grade cervical intraepithelial neoplasia using blood testing.
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHigh-grade cervical intraepithelial neoplasia (CIN2/3) is a critical precursor to cervical cancer, yet current screening methods (e.g., HPV testing, colposcopy) face challenges in accessibility and invasiveness, especially in resource-limited settings. We aimed to develop a non-invasive, machine learning (ML)-based model using routine blood biomarkers. This model is intended to assess the risk of high-grade CIN and potentially serve as a triage tool before colposcopy.
methodsData were collected from two groups: 128 high-grade CIN (CIN2/3) and 120 low-grade CIN (CIN1) patients. A total of 29 clinical characteristics and blood test measurements were considered for use in model development. Four feature selection algorithms (F-test, LASSO regression, decision tree, and random forest) were used to identify key predictors, and 11 machine learning algorithms were employed for model training. The dataset was split into training (70%) and testing (30%) cohorts. Model performance was evaluated using learning curves, receiver operating characteristic curves (ROC), area under the curve (AUC), Brier score, calibration curves, Precision-Recall (PR) curves, and Decision Curve Analysis (DCA). A web-based calculator was developed for clinical deployment. We assessed feature importance using the SHapley Additive exPlanation (SHAP) approach.
resultsKey features selected for the model included creatinine (CREA), red blood cell count (RBC), neutrophil ratio (NEU%), direct bilirubin (DBIL), and monocyte count (MON). The Support Vector Machine (SVM) algorithm achieved the best predictive performance, with an AUC of 0.75 (95% CI: 0.69–0.80) and a Brier score of 0.21 (95% CI: 0.17–0.28). By employing the SHAP method, we identified the variables that contributed to the model. The web tool ( https://dvhl6xsf29zmdewixjx7kz.streamlit.app ) provides real-time risk stratification.
conclusionsThe model demonstrated strong performance across various validation metrics, with the SVM algorithm achieving an AUC of 0.75, indicating potential clinical utility. We also developed a web-based calculator to estimate high-grade CIN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.